Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

inflammation/phosphatase

Nuoroda įrašoma į mainų sritį
Puslapis 1 nuo 24 rezultatus

Alkaline phosphatase for treating an inflammatory disease of the gastro-intestinal tract

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION The current invention relates to the field of medicine and in particular to the use of LPS detoxifying and neutralizing enzymes. The present invention also relates to the field of pharmacy and in particular to the pharmaceutical use of alkaline phosphatase enzymes. BACKGROUND
FIELD OF THE INVENTION This invention relates to a method of inhibiting Protein Tyrosine Phosphatase 1B (PTP1B) and/or T-cell Protein Tyrosine Phosphatase (TC-PTP) and/or Protein Tyrosine Phosphatases (PTPases) having an aspartic acid (Asp) in position 48 (PTP1B numbering, Chernoff et al., Proc.

Protein tyrosine phosphatase inhibitors and methods of use thereof

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION This invention relates to the field of protein tyrosine phosphatase inhibition. BACKGROUND OF THE INVENTION This invention relates to a novel class of phosphonic acid derivatives that are inhibitors of PTP-1B. Reversible protein tyrosine phosphorylation, coordinated by the

Protein tyrosine phosphatase inhibitors and methods of use thereof

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION This invention relates to the field of protein tyrosine phosphatase inhibition. BACKGROUND OF THE INVENTION This invention relates to a novel class of phosphonic acid derivatives that are inhibitors of PTP-1B. Reversible protein tyrosine phosphorylation, coordinated by the

Modified phosphatases

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION The invention relates to phosphatases and more in specific to (genetically) modified phosphatases, pharmaceutical compositions comprising (genetically) modified phosphatases and the use of (genetically) modified phosphatases for treating or curing for example sepsis,

Regulation of human protein phosphatase IIc-like enzyme

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
TECHNICAL FIELD OF THE INVENTION The invention relates to the regulation of human protein phosphatase IIC-like enzyme activity for therapeutic effects. BACKGROUND OF THE INVENTION The protein phosphorylation/dephosphorylation cycle is one of the major regulatory mechanisms employed by eukaryotic

Methods of using thiazolidine derivatives to treat cancer or inflammation

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION This invention is directed to methods of using thiazolidine derivatives to treat cancer or inflammation in a mammal. BACKGROUND OF THE INVENTION Protein tyrosine phosphorylation is an important mechanism for transmitting extracellular stimuli in biochemical and cellular events

Mannose-6-phosphonate compounds for the treatment of inflammatory diseases

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to novel phosphotetrahydropyran compounds, primarily derivatives of mannose-6-phosphate, and their use in treating diseases or disorders that are mediated at least in part by T lymphocyte emigration from

Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION This invention relates to a biocompatible, non-inflammatory, collagen conjugate material, described herein in the form of a porous membrane structure, and to a process for making this material. While individual components of this system are known in the art and in the

1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase)

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
This application is the National Stage of Application No. PCT/EP2006/046543, filed on Dec. 6, 2006, which claims benefit under 35 U.S.C. .sctn.119(a-d) of U.S. Provisional Application No. 60/748,491, filed Dec. 8, 2005, the contents of which are incorporated herein by reference in their
FIELD OF THE INVENTION The present invention provides methods for modulating SET activity by contacting SET with a binding agent. In one embodiment, the binding agent is an ApoE peptide derivative. The invention provides methods for the treatment of inflammatory and neurological conditions by

Modulation of biological signal transduction by RNA interference

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION 1. Technical Field The present invention relates generally to compositions and methods useful for treating conditions associated with defects in cell proliferation, cell differentiation, and cell survival. The invention is more particularly related to double-stranded RNA

Modulation of PTPRA to treat arthritis

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND Fibroblast-like synoviocytes (FLS) in the intimal lining of the joint synovium control the composition of the synovial fluid and extracellular matrix (ECM) of the joint lining. In rheumatoid arthritis (RA), FLS become aggressive and invasive, contributing to many aspects of RA pathology.

Treating post-seizure patients

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION The field of the invention is treating post-seizure patients to interfere with epileptogenesis. The highest incidence of seizures during lifetime is found in the neonatal period and neonatal seizures lead to a propensity for epilepsy and long-term cognitive deficits. Here

Constrained tricyclic sulfonamides

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
FIELD OF THE INVENTION The invention relates to the use of tricyclic chemical modulators of PPA2 and FOXO transcription factor proteins to treat cancer, proteotoxicity induced neurodegeneration, stress-induced depression, inflammation, acne, and viral infections. BACKGROUND Protein kinases have
Prisijunkite prie mūsų
„Facebook“ puslapio

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

  • Dirba 55 kalbomis
  • Žolelių gydymas, paremtas mokslu
  • Vaistažolių atpažinimas pagal vaizdą
  • Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
  • Skaitykite mokslines publikacijas, susijusias su jūsų paieška
  • Ieškokite vaistinių žolelių pagal jų poveikį
  • Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais

Google Play badgeApp Store badge